OrthoPediatrics Q2 revenue $39.6M (+20% YoY); net loss $2.9M, FY guide reaffirmed

ORTHOPEDIATRICS CORP

2023-Q2 EPS reported -$0.43 revenue$71,147,000

Total revenue $39.6M, +20% vs $32.9M in Q2 2022; US +19%, international +25%.
Trauma & Deformity revenue $27.5M (+22%), Scoliosis $10.9M (+16%), Sports Med/Other $1.2M (+23%).
Gross margin 76% (flat YoY); operating expenses $35.6M (+24%).
Net loss $2.9M ($0.13 loss per share) vs $0.3M loss a year ago; adj. EBITDA $2.3M vs $2.1M.
FY 2023 revenue guidance reiterated at $148M–$151M (21–23% growth); adj. EBITDA expected $3M–$4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ORTHOPEDIATRICS CORP reported the second quarter ended June 30, 2023 results: revenue $39.6 million, net income $2.9 million, EPS $0.13 per basic and diluted share. Guidance reaffirmed.

Period: the second quarter ended June 30, 2023
Revenue: $39.6 million
Net income: $2.9 million
EPS: $0.13 per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

OrthoPediatrics Corp. Reports Second Quarter 2023 Financial Results Record Setting Quarterly Revenue of $39.6 million

View on SEC.gov

Browse all earnings releases →

ORTHOPEDIATRICS CORP filing history →

Source: SEC EDGAR

accession 0001425450-23-000098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.